China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage
China’s National Health Commission (NHC) has released the National Essential Medicines List (NEML) 2026 Edition,...
Policy / Regulatory
China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List
China’s National Medical Products Administration (NMPA), in coordination with the Ministry of Public Security and...
China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) unveiled the “PIONEER” (Propel...
Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target
The Guangdong Provincial Medical Products Administration, in collaboration with the Department of Industry and Information...
China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs
China’s Center for Drug Evaluation (CDE) has released the 108th batch of reference preparations for...
NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate
China’s National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National...
China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted
The National Organized Drug Joint Procurement Office announced the 12th batch of national organized drug...
Anhui Province Launches National Alliance for Monoclonal Antibody Biologics Volume-Based Procurement
The Anhui Provincial Healthcare Security Administration has formally invited other provinces to participate in a...
NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)
The National Medical Products Administration (NMPA) announced the 106th batch of reference drugs designated for...
China’s CDE Proposes Framework for Reference Listed Drug Selection Following Marketing Authorization Holder Changes for Foreign-Originator Drugs Manufactured Locally
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released two...
China’s National Health Commission Revises Physician Practice Regulations to Align with Physicians Law and Enhance Multi-Site Practice Framework
The National Health Commission (NHC) announced comprehensive revisions to five key regulatory frameworks governing physician...
China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment
China’s National Healthcare Security Administration (NHSA) announced that the application period for the 2026 adjustment...
China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added
China’s Center for Drug Evaluation (CDE) has published the 107th batch of reference preparations for...
PKU Hi-Tech Huatai Pharmaceuticals Blacklisted from China’s Volume-Based Procurement Following Quality Compliance Failures
PKU Hi-Tech Huatai Pharmaceuticals Co., Ltd. has been blacklisted from China’s national volume-based procurement (VBP)...
China’s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards
China’s National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese...
China’s National Health Commission Launches Anti-Corruption Campaign Targeting Pharmaceutical Sales and Healthcare Services Misconduct
China’s National Health Commission (NHC) released the “Notice on Key Points for Rectifying Misconduct in...
China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
China’s National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs...
FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing
The U.S. Food and Drug Administration (FDA) released draft guidance on June 2, 2026, designed...
China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030
China’s National Health Commission (NHC) has released the “Notice on Further Improving the Urban Community...
China’s NMPA Introduces Comprehensive Medical Device Classification Reforms with 2-5 Year Transitional Periods
China’s National Medical Products Administration (NMPA) released two landmark regulatory announcements this week: the “Announcement...